Interventions of Interest
For questions please contact [email protected].
- nomlabofusp (Larimar Therapeutics, Inc.)
- omaveloxolone (Skyclarys®, Biogen Inc.)
Friedreich’s Ataxia
An assessment of nomlabofusp and omaveloxolone
Public Meeting
January 2027
Assessment Status
Open
Upcoming Milestone
Revised Scoping DocumentView
Main Review
January 21, 2027
New England CEPAC
The New England CEPAC 2027 public meeting on nomlabofusp and omaveloxolone for Friedreich’s Ataxia.
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- Biogen Inc.
- Friedreich’s Ataxia Research Alliance (FARA)
- Larimar Therapeutics
- National Ataxia Foundation (NAF)
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Public Comment Period
See Full Timeline
05/26/2026 - 06/16/2026
Public Comments on Draft Scoping Document
Related Assessments & Policy Papers.
Spinal Muscular Atrophy
Aug 2025Duchenne Muscular Dystrophy
Jul 2019Spinal Muscular Atrophy
Mar 2019
05/26/2026 - 06/16/2026
Public Comments on Draft Scoping Document
07/07/2026
Research Protocol
Please find the research protocol here:
08/21/2026
Model Analysis Plan
Please find the model analysis plan here:
12/10/2026
Evidence Report
01/21/2027
Evidence Presentation
02/18/2027
Public Comments
OpenView
Closed